1. Home
  2. NCNA vs PMCB Comparison

NCNA vs PMCB Comparison

Compare NCNA & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NuCana plc

NCNA

NuCana plc

HOLD

Current Price

$2.00

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.71

Market Cap

8.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCNA
PMCB
Founded
1997
1996
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7M
8.2M
IPO Year
2017
2001

Fundamental Metrics

Financial Performance
Metric
NCNA
PMCB
Price
$2.00
$0.71
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
38.0K
309.9K
Earning Date
06-01-2026
03-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
277.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.03
$0.63
52 Week High
$10.00
$1.51

Technical Indicators

Market Signals
Indicator
NCNA
PMCB
Relative Strength Index (RSI) 44.41 45.20
Support Level $1.83 $0.66
Resistance Level $2.28 $0.80
Average True Range (ATR) 0.16 0.06
MACD -0.01 -0.01
Stochastic Oscillator 5.49 13.29

Price Performance

Historical Comparison
NCNA
PMCB

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: